Previous 10 | Next 10 |
Alkermes (ALKS) receives FDA orphan designation for its fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha in the treatment of mucosal melanoma.Among the benefits of Orphan Drug status in the U.S. is a seven-year period ...
Alkermes to Hold Virtual Investor Day PR Newswire DUBLIN , March 4, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that it will hold a virtual Investor Day on Thursday, March 25, 2021 , beginning at 9:00 a.m. ET ( 1:00 p.m. GMT...
Stocks are correcting after getting over-extended. Market leadership is shifting by sector and industry. Strong stocks can bounce back when the sell-off subsides. For further details see: Top Stocks To Buy On The Sell-Off
Alkermes to Take Part in SVB Leerink 10th Annual Global Healthcare Conference PR Newswire DUBLIN , Feb. 18, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at the SVB Leerink Glo...
Image source: The Motley Fool. Alkermes PLC (NASDAQ: ALKS) Q4 2020 Earnings Call Feb 11, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Alkermes PLC (ALKS) Q4 2020 Earnings Call Transcript
Alkermes plc (ALKS) Q4 2020 Earnings Conference Call February 11, 2021 08:00 AM ET Company Participants Sandra Coombs - Vice President, Investor Relations Richard Pops - Chief Executive Officer Iain Brown - Chief Financial Officer Todd Nichols - Chief Commercial Officer Conference Call Partic...
The following slide deck was published by Alkermes plc in conjunction with their 2020 Q4 earnings call. For further details see: Alkermes plc 2020 Q4 - Results - Earnings Call Presentation
Alkermes (NASDAQ: ALKS) proved to be a disappointment for investors last year, with its stock slipping while the overall market soared. However, the biotech is off to a pretty good start in 2021. That good start isn't as strong as it was. Alkermes announced its fourth-quarter re...
Alkermes (ALKS) Q4 results:Revenues: $280M (-32.2%); FY Vivitrol sales: $310.7M (+7%); FY Aristrada sales: $241M (+27%); FY Manufacturing and royalty revenues of $484M, compared to $447.9M in the prior year.Net loss: ($42.64M), compared with ($5.35M) in the year-ago period...
Alkermes (ALKS): Q4 Non-GAAP EPS of $0.10 beats by $0.03; GAAP EPS of -$0.27 misses by $0.08.Revenue of $280M (-32.2% Y/Y) beats by $11.31M.Press Release For further details see: Alkermes EPS beats by $0.03, beats on revenue
News, Short Squeeze, Breakout and More Instantly...
Alkermes to Report Second Quarter Financial Results on July 24, 2024 PR Newswire DUBLIN , July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, ...
2024-06-29 16:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-19 17:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...